Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Files An 8-K Regulation FD Disclosure
Item7.01.
| Regulation FD Disclosure. |
A copy of the slide presentation that will be used by
representatives of Karyopharm Therapeutics Inc. (the Company) in
connection with investor meetings and presentations from time to
time (the Corporate Presentation) is attached to this Current
Report on Form 8-K as Exhibit 99.1. The Corporate Presentation is
current as of January9, 2017, and the Company disclaims any
obligation to correct or update this material in the future.
The information in this Form 8-K (including Exhibit 99.1) shall
not be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.
Item9.01. |
Financial Statements and Exhibits. |
(d) |
Exhibits |
The following exhibit relating to Item 7.01 shall be deemed to be
furnished, and not filed:
99.1 Corporate Presentation current as of January9, 2017
About Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Recent Trading Information
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) closed its last trading session down -0.06 at 10.95 with 311,867 shares trading hands.
